Background
Multi-institutional Canadian cohort. 2,483 patients with stage I testicular germ cell tumors (1,139 seminoma, 1,344 NSGCT) from 7 institutions managed on active surveillance, 1981–2005 — the largest such cohort at publication. Median follow-up 6.8 years.
Interventions and follow up
Strategy: Active surveillance after orchidectomy — periodic exam, tumor markers, and CT imaging; no adjuvant treatment (n=2,483)
Salvage: Relapse managed with chemotherapy (BEP) or radiotherapy
Primary endpoint: Relapse rate, relapse characteristics, and cancer-specific survival
Median follow up: 6.8 years
Salvage: Relapse managed with chemotherapy (BEP) or radiotherapy
Primary endpoint: Relapse rate, relapse characteristics, and cancer-specific survival
Median follow up: 6.8 years
Results
5-yr relapse rate (seminoma): 15.7%
5-yr relapse rate (NSGCT): 28.4%
5-yr cancer-specific survival: 99.7% (seminoma), 99.1% (NSGCT)
Relapse pattern: Most seminoma relapses at retroperitoneal nodes, salvaged with RT or chemotherapy with excellent outcomes
Very late relapse (>5 years): Rare but observed in both histologies
5-yr relapse rate (NSGCT): 28.4%
5-yr cancer-specific survival: 99.7% (seminoma), 99.1% (NSGCT)
Relapse pattern: Most seminoma relapses at retroperitoneal nodes, salvaged with RT or chemotherapy with excellent outcomes
Very late relapse (>5 years): Rare but observed in both histologies
Adverse events
Surveillance phase: No treatment-related toxicity; cumulative CT imaging entails radiation exposure
Salvage phase: Toxicity confined to relapsing patients receiving BEP chemotherapy or RT, with standard expected profiles (myelosuppression, neuropathy, GI effects)
Salvage phase: Toxicity confined to relapsing patients receiving BEP chemotherapy or RT, with standard expected profiles (myelosuppression, neuropathy, GI effects)
Conclusions
Active surveillance for stage I testicular GCTs yields excellent cancer-specific survival (>99%), comparable to adjuvant approaches, while sparing most patients any treatment-related toxicity. Relapse is predominantly detected at early, curable stages in a properly surveilled population.
Key Limitations
Retrospective design with heterogeneous surveillance schedules across 7 institutions over 25 years. Surveillance compliance cannot be verified retrospectively. Results reflect referral-center populations and may not generalize to community settings with lower adherence. Late relapses beyond 5 years warrant continued follow-up.
Clinical Context
This landmark series, alongside SWENOTECA data, established active surveillance as the preferred management for stage I seminoma and NSGCT in compliant, low-risk patients. EAU and ESMO guidelines recommend surveillance as the default for stage I testicular GCTs, with adjuvant carboplatin (seminoma) or BEP ×1 (NSGCT) reserved for high-risk features or surveillance-intolerant patients.
References